The pharmacokinetics data from Empros first trial is published. The data demonstrates that EMP16 has a safety comparable to Xenical.
Meny
Empros Pharma was founded in 2013 by researchers and entrepreneurs at Uppsala University together with the investor Flerie Invest. The company is developing EMP16, a pharmaceutical weight management treatment, planned to be ready for launch in 2027.
Pages
Meny
© 2024 empros pharma
Hemsidan är byggd av Weblab